Skip To Content

News & Events

Given the activity level of our attorneys, we are confident in showcasing the various matters that our clients have given us the privilege to work on and approved to post here.

Posts

  • May 01 2017

    The Deal issued its quarterly PIPE league tables, revealing that 2017’s first quarter outperformed last year’s first quarter. Deals were up nearly 75% from the previous year to 367, while dollars raised were up almost 70% to $21.3 billion.

    EG&S is top ranked.  Click here to read the article.

  • May 01 2017

    CytRx Corporation announced the closing of their Registered Direct in the amount of $15,000,000.  EG&S acted as counsel to the Placement Agent.

  • April 28 2017

    BioPharm X Corporation announced the closing of their Registered Direct offering in the amount of $5,000,001.  EG&S acted as counsel to the lead Investor.

  • April 27 2017

    Aeterna Zentaris Inc. announced the implementation of their At the Market offering in the amount of $6,944,000.  EG&S acted as counsel to the Placement Agent.

  • April 26 2017

    Apricus Biosciences, Inc. announced the closing of their Underwritten offering in the amount of $7,042,000.  EG&S acted as counsel to the Underwriter.

  • April 24 2017

    Sunshine Heart, Inc. announced the closing of their Underwritten offering in the amount of $8,372,000.  EG&S acted as counsel to the Underwriter.

  • April 21 2017

    Social Reality Inc. announced the closing of their PIPE offering in the amount of $5,000,000.  EG&S acted as counsel to the lead Investor.

  • April 19 2017

    DelMar Pharmaceuticals, Inc. announced the closing of their Registered Direct offering in the amount of $9,000,000.  EG&S acted as counsel to the Placement Agent.

“It’s with genuine appreciation to all of our clients that we are in a position to achieve and maintain our leadership position in so many areas.”